Earnings Per Share (GAAP)
$-2.19
vs $-0.41 est.
Revenue
$0
vs $0 est.
Analyst sentiment remains constructive. Despite the loss, the analyst community maintains a bullish stance with 9 Buy ratings and 1 Hold rating among the 10 analysts covering the stock. Shares closed at $22.23, near the 52-week high of $23.56 and well above the 52-week low of $1.60. Trading volume reached 250,901 shares.
What to Watch: Monitor the company’s next clinical trial readout and cash runway disclosure in the 10-K filing. With operating losses exceeding $66 million, the burn rate and financing strategy will determine how long Alto can fund its neuroscience programs before needing additional capital.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.